Risperidone

NCT00236379 – A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder

Posted on December 20, 2018 by tsuperadmin -

NCT00216632 – Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR)

Posted on December 20, 2018 by tsuperadmin -

NCT00369239 – Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta?

Posted on December 20, 2018 by tsuperadmin -

NCT00216671 – Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode

Posted on December 20, 2018 by tsuperadmin -

NCT00249223 – Risperidone Depot (Microspheres) vs. Risperidone Tablets – a Non-inferiority, Efficacy Trial in Subjects With Schizophrenia

Posted on March 8, 2018 by tsuperadmin -

NCT00044681 – A Study to Evaluate the Efficacy, Safety and Maintenance Effect of Risperidone Augmentation of SSRI Monotherapy in Young and Older Adult Patients With Unipolar Treatment-Resistant Depression

Posted on August 24, 2017 by tsuperadmin -

NCT00246246 – A Randomized, Open-label Trial of RISPERDAL® CONSTA™ Versus Oral Antipsychotic Care in Subjects With Bipolar Disorder

Posted on November 2, 2016 by tsuperadmin -

An open-label, long-term study of risperidone for the treatment of behavioral disturbances in patients with dementia

Posted on May 9, 2016 by tsuperadmin -

The safety and efficacy of risperidone 8 mg qd and 4 mg qd compared to placebo in the treatment of schizophrenia

Posted on March 31, 2016 by tsuperadmin -

NCT00253123 – A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia

Posted on March 31, 2016 by tsuperadmin -